#United States #Robbins Geller #San Diego #class action lawsuit #Capricor Therapeutics

Investor Alert: Capricor Therapeutics Class Action Deadline Approaching

As of September 10, 2026, investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR), who experienced significant financial losses, have a crucial opportunity to lead a class action lawsuit against the company. This lawsuit targets the alleged violations committed by Capricor and its executives under the Securities Exchange Act of 1934. The deadline for aspiring lead plaintiffs is set for September 28, 2026.

Allegations Against Capricor Therapeutics

Capricor is recognized for its focus on developing innovative therapies for Duchenne muscular dystrophy (DMD), a severe genetic condition causing muscle degeneration. However, allegations within the class action case suggest that the company misled investors about the safety and efficacy of its primary product, Deramiocel. The complaint outlines several disturbing assertions:

• - Changes to the statistical analysis plan for clinical trial data were not approved by the FDA prior to the submission of crucial documentation.
• - The lack of disclosure regarding these changes posed a substantial risk to the regulatory approval of Deramiocel, a vital treatment for DMD complications.

On July 27, 2026, the FDA released documentation ahead of a critical advisory meeting. This documentation indicated Capricor's changes to the statistical analysis plan were both unapproved and potentially detrimental to the review process. The FDA's commentary labeled the adopted analyses as scientifically unjustified, implying serious concerns about the data's integrity.

Furthermore, during an advisory meeting on July 29, 2026, an advisory panel voted against the approval of Deramiocel due to insufficient evidence backing its efficacy for treating DMD-related heart issues. This resulted in a significant drop in Capricor's share price, further compounding losses for investors.

The Role of the Lead Plaintiff in the Class Action

The Private Securities Litigation Reform Act of 1995 establishes the right for any investor who purchased Capricor's securities during the defined class period to seek the role of lead plaintiff. This individual is typically someone who stands to gain the most from the group's potential recovery and should reflect the interests of the broader class involved.

Once appointed, the lead plaintiff collaborates with a law firm to guide the lawsuit against Capricor, advocating for the collective rights of all damaged investors. Notably, your involvement as a lead plaintiff does not impact your chances of recovering damages through the final provided settlement to all eligible class members.

About Robbins Geller Rudman & Dowd LLP

Robbins Geller is a prominent law firm recognized for its relentless pursuit of justice for investors affected by securities fraud. According to their latest report, the firm has secured over $916 million in settlements for investors in 2025 alone, marking a continued commitment to investor rights. Clients considering participation in this lawsuit can find more information on their official website and reach out to representatives for inquiries personally.

For victims of investment fraud through Capricor Therapeutics, this is a critical moment to reclaim losses and hold the responsible parties accountable. Investors should act promptly to preserve their opportunities in this class action lawsuit before the September 28 deadline. Don’t miss your chance to stand united in the pursuit of justice for misconduct in the biotech industry.

Next Steps for Interested Investors

- Submit your information through the class action website to express your interest in leadership of the lawsuit.
- Contact Robbins Geller by calling 800-851-7783 or via email for direct inquiries.
- Stay informed about the lawsuit's progress and participate actively to advocate for your rights as an investor.

In the complex landscape of biotechnology investments, such class actions are instrumental in addressing misrepresentation and ensuring regulatory accountability.

Together, investors can navigate the challenges posed by corporate misconduct and foster a more transparent investment environment.